What's in Taiho Pharmaceutical Co., Ltd.'s pipeline?

Taiho Pharmaceutical Co., Ltd. has 26 drugs in our index: 1 marketed, 0 filed, 10 in Phase 3, 9 in Phase 2, 6 in Phase 1.

Which companies overlap with Taiho Pharmaceutical Co., Ltd.'s portfolio?

Top competitors by shared drug class: Sun Yat-sen University, Federation Francophone de Cancerologie Digestive, The First Affiliated Hospital with Nanjing Medical University, Asan Medical Center, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/taiho-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Taiho Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Taiho Pharmaceutical Co., Ltd. pipeline: 1 marketed, 0 filed, 10 Phase 3, 9 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 10 Phase 3 9 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Jeselhy	Pimitespib	marketed		Heat shock protein HSP 90-beta	Oncology
Placebo [Ambulatory Cohort] only	Placebo [Ambulatory Cohort] only	phase 3
TS-1 and cisplatin	TS-1 and cisplatin	phase 3	Antineoplastic agent	DNA	Oncology
Gemcitabine plus TS-1	Gemcitabine plus TS-1	phase 3	Combination chemotherapy		Oncology
Cisplatin (arm B)	Cisplatin (arm B)	phase 3	Platinum-based chemotherapy agent	DNA	Oncology
UFT (uracil, tegafur)	UFT (uracil, tegafur)	phase 3	Fluoropyrimidine antimetabolite	Thymidylate synthase	Oncology
S-1 plus Cisplatin	S-1 plus Cisplatin	phase 3	Antineoplastic agents	Thymidylate synthase, DNA	Oncology
S-1 plus CDDP	S-1 plus CDDP	phase 3	Combination chemotherapy (fluoropyrimidine + platinum agent)	Thymidylate synthase (S-1); DNA (CDDP)	Oncology
S-1 + Cisplatin (arm A)	S-1 + Cisplatin (arm A)	phase 3	Fluoropyrimidine + platinum-based chemotherapy combination	Thymidylate synthase (S-1); DNA (cisplatin)	Oncology
TAS-118 plus Oxaliplatin	TAS-118 plus Oxaliplatin	phase 3	Thymidylate synthase inhibitor	Thymidylate synthase	Oncology
cyclophosphamide, methotrexate, and fluorouracil	cyclophosphamide, methotrexate, and fluorouracil	phase 3

Therapeutic area mix

Oncology · 10

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sun Yat-sen University · 3 shared drug classes
Federation Francophone de Cancerologie Digestive · 3 shared drug classes
The First Affiliated Hospital with Nanjing Medical University · 2 shared drug classes
Asan Medical Center · 2 shared drug classes
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Japan Clinical Oncology Group · 2 shared drug classes
Beijing Biostar Pharmaceuticals Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Taiho Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Taiho Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/taiho-pharmaceutical-co-ltd. Accessed 2026-05-16.